Best Medical International, Inc. v. Eckert & Ziegler Nuclitec GMBH

565 F. App'x 232
CourtCourt of Appeals for the Fourth Circuit
DecidedApril 8, 2014
Docket13-1708
StatusUnpublished
Cited by5 cases

This text of 565 F. App'x 232 (Best Medical International, Inc. v. Eckert & Ziegler Nuclitec GMBH) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Best Medical International, Inc. v. Eckert & Ziegler Nuclitec GMBH, 565 F. App'x 232 (4th Cir. 2014).

Opinion

AGEE, Circuit Judge:

In a prior decision involving these parties, we affirmed the district court’s judgment on the merits with the exception of an award of attorneys’ fees and costs. See Best Med. Int’l, Inc. v. Eckert & Ziegler Nuclitec GmbH, 505 Fed.Appx. 281 (4th Cir.2013). We concluded that Eckert & Ziegler Nuclitec GmbH (“EZN”) was the prevailing party in its litigation against Best Medical International, Inc. and Best Vascular, Inc. (collectively “Best”). However, we vacated that part of the district court’s judgment awarding fees and costs to EZN because that award did not reflect the required analysis under Johnson v. Ga. Highway Express, Inc., 488 F.2d 714, 717-19 (5th Cir.1974). Accordingly, we remanded the attorneys’ fees and costs portion of the prior judgment to the district court so that it could undertake “a further analysis that [took] into account the applicable Johnson factors.” Best Med., 505 Fed.Appx. at 284.

In a thorough opinion, the district court conducted the Johnson analysis and awarded EZN fees and costs. Best now appeals that decision. For the reasons set forth below, we affirm the district court’s judgment.

I.

We need not discuss all the specifics of the underlying litigation, as that matter is fully covered in our prior opinion. See Best Med., 505 Fed.Appx. at 282-84. Nonetheless, we briefly summarize certain facts that are useful to understand the context in which the current appeal arises.

A.

In 1999, AEA Technology-QSQ GmbH (“QSA”) entered into a manufacturing agreement with one of Best’s predecessors. Under that agreement, QSA was to manufacture “sources” or “source trains” of strontium and sell that product to Best’s predecessor. At the end of that contract, Best was obligated to decontaminate and decommission QSA’s manufacturing production lines in Germany used to make these sources.

Best failed to decontaminate the manufacturing line as agreed, so QSA sued to enforce the contractual covenant.

QSA and Best settled QSA’s suit under a 2008 Settlement Agreement that provided Best was to complete its decontamination work by a certain date and post a performance bond. Best was also required to buy minimum orders of “source trains” that met defined specifications. Furthermore, the Settlement Agreement provided that “the prevailing party [would] *234 be entitled to recover ... reasonable attorneys’ fees and costs incurred” in “any litigation” “brought for breach” of the agreement. (J.A. 62.)

The Settlement Agreement soon unraveled. Best did not timely perform the required decontamination work, which caused EZN (having acquired QSA in 2009) to notify Best in 2010 that it planned to do the work at Best’s expense. Best also did not post the performance bond. For its part, Best complained that EZN was producing strontium sources that did not meet the specifications found in the parties’ original manufacturing agreement.

B.

When the Settlement Agreement broke down, Best initiated a suit raising three principal complaints:

(1) that EZN was equitably estopped from conducting the decontamination and decommission task and from disposing of the production line in the course of decontaminating and decommissioning the production line; (2) that EZN breached the Settlement Agreement by not cooperating with Best; and (3) that EZN breached the Settlement Agreement by not providing Best with source trains and sources that met the specifications of the original Manufacturing Agreement.

Best Med., 505 Fed.Appx. at 283. Best sought certain injunctive relief (including an injunction to stop EZN from breaking the line down), sought “any monetary damages that [Best] sustained as a result of [EZN]’s actions,” and sought a refund, of payments that it made for the supposedly “non-compliant” sources. (J.A. 51.) The parties agreed that Best’s requested relief would have been valued at no less than $8 million.

In response, EZN filed a four-count compulsory counterclaim under Federal Rule of Civil Procedure 13, alleging:

(1) that Best breached the Settlement Agreement by failing to post a performance bond; (2) that Best breached the Settlement Agreement by failing to decontaminate and decommission the production line; (3) that Best fraudulently induced EZN to enter into the Settlement Agreement; and (4) that EZN should be awarded declaratory relief stating that Best had defaulted under the Settlement Agreement and that its default relieved EZN from any obligation to dispose of sources.

Best Med., 505 Fed.Appx. at 283.

Upon cross motions for summary judgment, the district court ruled largely for EZN. See Best Med. Int’l, Inc. v. Eckert & Ziegler Nuclitec GmbH, No. 1:10-cv-617, 2011 WL 3951675 (E.D.Va. Sept. 7, 2011). The court held that Best had not adequately established any of its claims. Further, the court determined that two of the four EZN counterclaims had not been shown. As to EZN’s second counterclaim, the court concluded that Best had defaulted on its obligation under the Settlement Agreement to decommission and decontaminate the German production lines, but found that any damages claim should be arbitrated — under an arbitration clause in the Settlement Agreement — once EZN completed its own cleanup efforts. The district court dismissed the declaratory judgment count as “moot” because the court had “ruled on all points raised” in that count. Id. at *7.

EZN and Best each moved for attorneys’ fees and costs under the Settlement Agreement. After determining that EZN was the prevailing party, the district court proceeded to determine an appropriate amount of attorneys’ fees and costs. The district court began by detailing the appropriate analysis. First, the district court *235 recognized that it was to determine the lodestar figure by multiplying the number of reasonable hours by a reasonable fee. The district court acknowledged that it was to assess reasonableness by looking to the twelve factors in Johnson, 488 F.2d at 717-19. Second, the district court correctly explained that it was to deduct fees for time spent on unsuccessful claims. Third, the district court stated that it was to award some percentage of the remaining fees to account for the degree of success enjoyed by the prevailing party. Applying this analysis, the district court then awarded EZN attorneys’ fees of $584,735.08 and costs of $32,892.61. The district court found those sums reasonable after “[t]aking the Johnson factors into account.” (J.A. 588.) The award also reflected an approximately $38,000 voluntary reduction by EZN for fees related to (1) pre-litigation activity, (2) its unsuccessful fraud claim, and (3) an unsuccessful motion to compel. The district court concluded that no further reduction was necessary to reflect EZN’s lack of success on its counterclaims because “there was no duplication involved over and above the effort to defend itself against the claims in this case.” (J.A. 589.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
565 F. App'x 232, Counsel Stack Legal Research, https://law.counselstack.com/opinion/best-medical-international-inc-v-eckert-ziegler-nuclitec-gmbh-ca4-2014.